Your browser is no longer supported. Please, upgrade your browser.
Settings
NNVC NanoViricides, Inc. daily Stock Chart
NNVC [AMEX]
NanoViricides, Inc.
Index- P/E- EPS (ttm)-2.08 Insider Own14.97% Shs Outstand3.85M Perf Week-1.83%
Market Cap56.55M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float6.31M Perf Month29.43%
Income-7.80M PEG- EPS next Q- Inst Own26.00% Short Float5.18% Perf Quarter-20.84%
Sales- P/S- EPS this Y11.10% Inst Trans- Short Ratio0.26 Perf Half Y130.67%
Book/sh2.00 P/B3.76 EPS next Y- ROA-60.00% Target Price- Perf Year41.94%
Cash/sh0.09 P/C80.79 EPS next 5Y- ROE-78.10% 52W Range1.27 - 19.20 Perf YTD199.60%
Dividend- P/FCF- EPS past 5Y15.10% ROI- 52W High-60.83% Beta1.10
Dividend %- Quick Ratio0.30 Sales past 5Y- Gross Margin- 52W Low491.52% ATR0.99
Employees17 Current Ratio0.30 Sales Q/Q- Oper. Margin- RSI (14)49.27 Volatility7.87% 11.86%
OptionableNo Debt/Eq0.14 EPS Q/Q22.20% Profit Margin- Rel Volume0.29 Prev Close7.33
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.28M Price7.52
Recom- SMA20-4.51% SMA5012.90% SMA20051.23% Volume367,089 Change2.59%
Feb-11-15Initiated Midtown Partners Strong Buy $5.30
May-26-20 06:15AM  NanoViricides Announces Completion of $10.2 Million Registered Direct Offering - Funds to Accelerate COVID-19 Drug Program and HerpeCide Program ACCESSWIRE
May-21-20 08:30AM  NanoViricides Announces Pricing of $10.2 Million Registered Direct Offering ACCESSWIRE -15.73%
May-20-20 06:15AM  Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus ACCESSWIRE -5.80%
May-18-20 06:15AM  Honorable Ex-Congressman Todd Rokita Joins the Board of Directors of NanoViricides, Inc. ACCESSWIRE +5.30%
May-13-20 10:12AM  Company News for May 13, 2020 Zacks +15.57%
May-12-20 12:57PM  NanoViricides: New Covid-19 Drug Candidates Could Boost Performance GuruFocus.com +28.27%
06:15AM  NanoViricides Develops Highly Effective Broad-Spectrum Drug Candidates Against Coronaviruses ACCESSWIRE
May-04-20 06:15AM  NanoViricides Signs Confidential Disclosure Agreement with International Pharmaceutical Company to Explore Collaborating on its COVID-19 Program ACCESSWIRE +14.71%
Apr-29-20 06:15AM  NanoViricides Presentation on COVID-19 and Shingles Drug Development Update at the Planet MicroCap Showcase Virtual Investor Conference 2020 is Now Available ACCESSWIRE -6.29%
Apr-21-20 02:00PM  NanoViricides to Present COVID-19 and Shingles Drug Development Update at the Planet MicroCap Showcase Virtual Investor Conference 2020 on April 22nd ACCESSWIRE +33.62%
Apr-13-20 06:15AM  NanoViricides President Dr. Anil Diwan was Interviewed by Proactive Investors About the Companys Antiviral Drug Development Against SARS-CoV-2 to Treat COVID-19 ACCESSWIRE
Apr-07-20 02:31PM  Does NanoViricides, Inc. (NYSEMKT:NNVC) Have A High Beta? Simply Wall St.
11:49AM  NanoViricides: The Visit From Senator Blumenthal Is a Positive Development GuruFocus.com
Apr-06-20 06:15AM  U.S. Senator Richard Blumenthal Visited NanoViricides Inc. for Update on Coronavirus (COVID-19) Drug Development Efforts ACCESSWIRE
Mar-31-20 07:30AM  NanoViricides, Inc. Progress on COVID-19 Drug Encouraging Newsfile
Mar-16-20 06:15AM  Coronavirus Drug Development Update from NanoViricides, Inc. ACCESSWIRE +6.12%
Mar-14-20 10:18AM  Inovio stock rallies after company gets Gates Foundation grant to test device for coronavirus vaccine MarketWatch
Mar-13-20 05:42PM  The Coronavirus Pandemic Has Revealed Some Micro-Cap Opportunities GuruFocus.com -9.74%
Mar-09-20 02:44PM  Is Inovio Pharmaceuticals Stock the Cure for Your Portfolio? InvestorPlace -17.96%
Mar-05-20 04:11PM  NanoViricides, Inc. Reports Discovery of Broad-Spectrum Virus-Binding Ligands; Expected to Counter COVID-19 Newsfile
Feb-28-20 04:57PM  Dow, S&P 500 fall for 7th straight day; stocks suffer biggest weekly fall since 2008 MarketWatch -7.95%
Feb-25-20 03:25PM  18 Medical Stocks To Watch Amid The Coronavirus Outbreak Benzinga -13.76%
Feb-24-20 08:39AM  NanoViricides stock soars amid fears of global spread of COVID-19 MarketWatch +38.37%
08:04AM  Benzinga Pro's Top 5 Stocks To Watch For Mon., Feb. 24, 2020: NNVC, WFC, SPCE, LL, CETX Benzinga
06:15AM  NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2019 - Has Sufficient Cash, HerpeCide(TM) Drug Candidate IND Application Development in Progress ACCESSWIRE
Feb-18-20 01:01PM  The Wuhan Virus and Research-Focused Biotech Companies GuruFocus.com
Feb-12-20 06:15AM  Dr. Mak Jawadekar Joins the Board of Directors of NanoViricides, Inc. ACCESSWIRE -7.03%
Feb-10-20 07:30AM  Nanoviricides President Dr. Diwan Was Interviewed by The Varney Show on Fox Business News ACCESSWIRE +17.41%
Feb-06-20 05:50PM  Can Biotech ETFs Continue to Soar in 2020? Zacks -7.91%
Feb-04-20 07:30AM  Nanoviricides President Dr. Diwan Was Interviewed By The Kennedy Show On Fox Business News ACCESSWIRE -6.38%
Feb-03-20 02:17PM  Coronavirus update: 361 have died, there are now 11 cases in the U.S. and the case count has doubled SARS MarketWatch -35.44%
08:59AM  Benzinga Pro's Top 5 Stocks To Watch For Mon., Feb. 3, 2020: SYY, PCG, NNVC, UBER, TSLA Benzinga
Feb-01-20 10:53AM  Coronavirus update: WHO says prepare for local coronavirus outbreaks in other countries MarketWatch
Jan-31-20 09:09AM  The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO Benzinga +39.67%
Jan-30-20 06:20PM  NanoViricides Confirms It Has Been Working On A Treatment For The Novel Wuhan Coronavirus ACCESSWIRE +26.58%
10:54AM  These 4 Biotech Stocks Are the Silver Lining on the Wuhan Coronavirus GuruFocus.com
Jan-28-20 02:23PM  Coronavirus update: Vaccine stocks retreat and airport screening expands to 20 U.S. airports MarketWatch -46.84%
07:53AM  Company News For Jan 28, 2020 Zacks
Jan-27-20 04:29PM  Dow ends more than 450 points lower as spread of coronavirus quashes buying sentiment MarketWatch +86.98%
04:03PM  Stock market news live: Stocks close lower as coronavirus death toll rises Yahoo Finance
02:21PM  CDC officials say coronavirus is similar to SARS, no new U.S. cases reported MarketWatch
10:58AM  Analyst: China's coronavirus victims 'probably 10 times' higher than reported Yahoo Finance
08:43AM  Vaccine, diagnostics stocks rise again on spreading coronavirus MarketWatch
Jan-24-20 10:45PM  NanoViricides Closes on $8.625 Million Underwritten Public Offering of Common Stock ACCESSWIRE +54.48%
03:08PM  Biotech ETFs Are Not Riding the Wave from Coronavirus Panic ETF Trends
Jan-23-20 03:14PM  The latest coronavirus stock screamers: Inovio Pharmaceuticals, Co-Diagnostics MarketWatch +43.19%
01:02PM  13 Coronavirus-Related Stocks To Watch Amid Wuhan Outbreak Benzinga
11:01AM  UPDATE: Vaccine stocks rise sharply as coronavirus fears mounts MarketWatch
10:18AM  3 Biotech Stocks Likely to Gain as Coronavirus Spreads Zacks
09:51AM  The Zacks Analyst Blog Highlights: Novavax, NanoViricides, Aethlon Medical and Oncolytics Biotech Zacks
06:54AM  Vaccine makers tap into virus-driven rally to raise money MarketWatch
Jan-22-20 09:09AM  Benzinga Pro's Top 5 Stocks To Watch For Wed., Jan. 22, 2020: NFLX, TSLA, NNVC, SKT, SPCE Benzinga -55.06%
08:12AM  Coronavirus Infects Wall Street: Stocks to Gain & Lose Zacks
Jan-21-20 08:35PM  NanoViricides Prices $7.5 Million Underwritten Public Offering of Common Stock ACCESSWIRE +152.98%
02:40PM  Experimental vaccine stocks jump on concerns about new virus in China MarketWatch
Jan-09-20 08:00AM  NanoViricides Successfully Completes Required Genetic Toxicology Testing of Lead Drug Candidate NV-HHV-101 ACCESSWIRE +17.08%
Jan-07-20 08:30AM  NanoViricides Has Initiated Genetic Toxicology Testing Required for an IND for Its Drug Candidate ACCESSWIRE -11.64%
Jan-06-20 07:30AM  NanoViricides Receives Cash Infusion of $2.25 Million ACCESSWIRE -6.47%
Dec-17-19 08:30AM  NanoViricides Inc.: Upcoming Human Clinical Trials Create Opportunity for Innovation ACCESSWIRE -7.96%
Dec-09-19 08:30AM  NanoViricides President Dr. Anil Diwan Provides Responses to Shareholder Questions at the Annual Meeting of Shareholders ACCESSWIRE
Dec-06-19 08:30AM  NanoViricides Annual Meeting of Shareholders to be Held on Saturday, December 7th, 2019 at the Sheraton Hotel, Stamford, CT ACCESSWIRE -7.20%
Dec-03-19 07:30AM  NanoViricides Founder Dr. Diwan Provides $2,000,000 Loan Commitment to the Company ACCESSWIRE -11.16%
Dec-02-19 07:30AM  NanoViricides Has Initiated Required Safety Pharmacology Assessment of Lead Drug Candidate towards IND ACCESSWIRE -5.63%
Nov-19-19 09:00AM  NanoViricides Files Quarterly Report for Period Ending September 30, 2019 - HerpeCide Drug Candidate IND Enabling Studies Update, Progressing Towards Clinical Trials ACCESSWIRE +8.72%
Nov-04-19 07:30AM  NanoViricides Completes Licensing for VZV Field which Includes Shingles Drug Development ACCESSWIRE
Oct-31-19 07:30AM  NanoViricides Initiates Required Dermal Sensitization and Ocular Irritation Testing of Lead Drug Candidate towards IND ACCESSWIRE
Oct-25-19 09:20AM  NanoViricides, Inc., Builds Promising Pipeline Targeting a Multi-Billion Dollar Market for Herpes and Shingles ACCESSWIRE +13.70%
Oct-09-19 07:30AM  NanoViricides Has Initiated Bio-analytical Studies as Part of IND-Enabling Safety and Toxicology Studies of Lead Candidate NV-HHV-101 ACCESSWIRE
Oct-03-19 07:30AM  NanoViricides is Creating Nanomedicines to Develop Antiviral Therapies to Combat Shingles and Herpes Viruses Interviewing with Proactive Investors, President & Chairman Anil R. Diwan Outlines the History and Cutting Edge Technology Driving Proprietary Therapies ACCESSWIRE -16.50%
Sep-30-19 07:30AM  NanoViricides, Inc. Files Form S-1 Registration Statement ACCESSWIRE -21.15%
Sep-20-19 11:33AM  What Percentage Of NanoViricides, Inc. (NYSEMKT:NNVC) Shares Do Insiders Own? Simply Wall St. +5.43%
Sep-12-19 09:00AM  NanoViricides, Inc. Announces One-for-Twenty Reverse Stock Split PR Newswire -7.04%
Aug-26-19 07:30AM  NanoViricides, Inc. Has Filed its Annual Report, Company Advancing Rapidly Towards First IND PR Newswire
Aug-05-19 07:00AM  NanoViricides Reports Its First Drug Candidate is on Track with GLP Safety/Toxicology Studies toward Human Clinical Trials PR Newswire
Jul-11-19 10:10AM  Does The NanoViricides, Inc. (NYSEMKT:NNVC) Share Price Fall With The Market? Simply Wall St.
Jun-10-19 07:00AM  NanoViricides, Inc. Appoints Dr. Mark Day to its Board of Directors PR Newswire
Jun-03-19 07:00AM  NanoViricides has Received Favorable FDA Comments on Its Pre-IND Application for the Lead Drug Candidate PR Newswire -9.09%
May-20-19 07:00AM  NanoViricides Files Quarterly Report for Period Ending March 31, 2019 - HerpeCide Drug Candidate Pre-IND Application Submitted, Progressing Towards Clinical Trials PR Newswire
Apr-24-19 01:00PM  Some NanoViricides (NYSEMKT:NNVC) Shareholders Have Taken A Painful 92% Share Price Drop Simply Wall St.
Apr-16-19 07:00AM  NanoViricides Submits Pre-IND Briefing Documents to the US FDA PR Newswire
Apr-09-19 09:00AM  NanoViricides Provides Update on Pre-IND Meeting with the US FDA, GLP Safety/Toxicology Studies to Begin Soon, Multiple Kg Scale Drug Production Accomplished at Its Own Facility PR Newswire +7.03%
Mar-26-19 07:00AM  NanoViricides has Requested a Pre-IND Meeting with the US FDA PR Newswire -5.14%
Mar-12-19 07:00AM  NanoViricides Reports Successful Completion of Another Important Safety Study towards an IND PR Newswire
Mar-05-19 07:00AM  NanoViricides Reports Excellent Safety Profile of Its First Drug Candidate in Dermal Treatment Study PR Newswire -11.59%
Feb-27-19 09:48AM  NanoViricides Announces $2.5 Million Financing in a Registered Direct Offering PR Newswire -31.44%
Feb-26-19 07:00AM  NanoViricides Reaches an Agreement on Terms of License for Shingles Virus Drug Development PR Newswire +40.29%
Feb-19-19 07:28AM  NanoViricides: Fiscal 2Q Earnings Snapshot Associated Press +8.97%
07:00AM  NanoViricides Files Quarterly Report for Period Ending December 31, 2018 - HerpeCide Drug Candidate Progressing in IND-Enabling Studies Towards Clinical Trials PR Newswire
Feb-11-19 07:00AM  NanoViricides President Dr. Diwan to Present at the BIO CEO & Investor 2019 Event in New York City Tomorrow Feb 12th at 2:30pm PR Newswire -6.80%
Feb-04-19 07:00AM  NanoViricides Has Initiated IND-Enabling Safety/Toxicology Studies for Its First Drug Candidate Moving towards Human Clinical Trials PR Newswire +11.11%
Jan-15-19 11:50AM  NNVC: Initiating Coverage Zacks Small Cap Research -7.57%
Jan-02-19 07:00AM  NanoViricides, Inc. CEO Dr. Taraporewala To Present At The Biotech Showcase Investment Conference In San Francisco on January 7, 2019 PR Newswire +12.60%
Nov-26-18 07:35AM  NanoViricides: Fiscal 1Q Earnings Snapshot Associated Press
07:00AM  NanoViricides Files Quarterly Report for Period Ending September 30, 2018 PR Newswire
Nov-13-18 10:35AM  NNVC: NanoViricides: Developing Antiviral Medication Using Nanotechnology Zacks Small Cap Research -14.38%
Oct-29-18 07:00AM  NanoViricides, Inc. Appoints Mr. James Sapirstein to its Board of Directors PR Newswire
Oct-22-18 07:00AM  NanoViricides CEO Dr. Irach Taraporewala Presents a Letter to Shareholders PR Newswire +9.23%
Oct-15-18 07:00AM  NanoViricides Has Filed its Annual Report, Company Reports Strong Progress in Advancement of HerpeCide Program PR Newswire -10.25%
Sep-28-18 07:00AM  NanoViricides Inc. to Present at the MicroCap Conference in New York City on October 1 PR Newswire -9.48%
Sep-26-18 07:22AM  Who Are The Major Shareholders Of NanoViricides Inc (NYSEMKT:NNVC)? Simply Wall St. -8.85%
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. Its products pipeline includes HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of all types of Dengue viruses; and HIVCide that is an escape-resistant anti-HIV nanoviricide. In addition, it is also involved in research and development of other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.